The fertile period of women's life compared to menopause is associated with a lower incidence of degenerative inflammatory diseases. In brain, estrogens ameliorate brain performance and have positive effects on selected neural pathologies characterized by a strong inflammatory component. We thus hypothesized that the inflammatory response is a target of estrogen action; several studies including ours provided strong evidence to support this prediction. Microglia, the brain's inflammatory cells, and circulating monocytes express the estrogen receptors ER-and ER-and their responsiveness in vivo and in vitro to pro-inflammatory agents, such as lipopolysaccharide (LPS), is controlled by 17 -estradiol (E 2 ). Susceptibility of central nervous system (CNS) macrophage cells to E 2 is also preserved in animal models of neuroinflammatory diseases, in which ER-seems to be specifically involved. At the molecular level, induction of inflammatory gene expression is blocked by E 2 . We recently observed that, differently from conventional antiinflammatory drugs, E 2 stimulates a nongenomic event that interferes with the LPS signal transduction from the plasma membrane to cytoskeleton and intracellular effectors, which results in the inhibition
file:///Users/rglaser/Desktop/DATA%20Articles/MS/Estrogen%20Action…nals%20of%20the%20New%20York%20Academy%20of%20Sciences.webarchive of the nuclear translocation of NF-B, a transcription factor of inflammatory genes. Interference with NF-B intracellular trafficking is selectively mediated by ER-. In summary, evidence from basic research strongly indicates that the use of estrogenic drugs that can mimic the anti-inflammatory activity of E 2 might trigger beneficial effects against neurodegeneration in addition to carrying out their specific therapeutic function.
